Assessing Medication Adherence in Patients With Chronic Recurrent Multifocal Osteomyelitis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Recurrent Multifocal Osteomyelitis
- Sponsor
- Seattle Children's Hospital
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Medication possession ratio (MPR)
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
This project aims to quantify and evaluate rates of non-adherence and barriers to medication adherence in pediatric patients with CRMO followed at Seattle Children's Hospital's robust CRMO program, which is the only clinical program in the Washington, Wyoming, Alaska, Montana, Idaho (WWAMI) region. This will be a stepped-wedge cluster-randomized trial, in which participants will be randomly assigned to one of two groups -- one which receives educational materials at the end of their first clinic visit, and the other which receives educational materials at the end of their second clinic visit. All participants will be given baseline surveys at the start of their first clinic visit, as well as follow-up surveys at the start of their second and third clinic visits. These surveys aim to evaluate rates of non-adherence and qualitative barriers to adherence, as well as efficacy of educational interventions in improving adherence rates.
Investigators
Yongdong (Dan) Zhao
Associate professor, attending physician
Seattle Children's Hospital
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of CRMO
- •Receives clinical care at Seattle Children's Hospital
- •On one or more scheduled prescription medications
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Medication possession ratio (MPR)
Time Frame: 6 to 9 months
The MPR is reported as a percentage calculated as: (total prescription days of supply/ (last prescription date - the first prescription date)). For example, if a patient only filled a one-month prescription twice during 6 months, so only had 60 days of medications available during the 6 months, the MPR would be 33%. A MPR of ≥0.8 is generally accepted as good compliance. The MPR data will be calculated for T0 and T1. In order to capture adequate data to calculate the MPR, refill data was acquired for 3 months prior to the beginning of the study (MPR T0) and for 3 months after T1 (MPR T1).
Secondary Outcomes
- Barriers to adherence(6-9 months)